Home Insights PharmaDispatch: Commercial Eyes founder wins Pat Clear Award

PharmaDispatch: Commercial Eyes founder wins Pat Clear Award

Posted on October 23, 2014

Commercial Eyes’ Managing Director, Andrew Carter, features in today’s issue of PharmaDispatch, reproduced here with the permission of www.pharmadispatch.com.au

Commercial Eyes founder wins Pat Clear Award

Medicines Australia has confirmed the founder and Managing Director of Commercial Eyes, Andrew Carter, as the recipient of this year’s Pat Clear Award.

The Pat Clear Award was established in 2002 to commemorate the substantial contribution Mr Clear made to the medicines industry in Australia during his 40-year career.

Mr Clear was a company managing director, CEO of Medicines Australia, when it was known as the Australian Pharmaceutical Manufacturers Association, and after retiring from industry was appointed to the Pharmaceutical Benefits Advisory Committee.

The award recognises a person or group’s significant commitment and contribution to the Australian research-based pharmaceutical industry.

Mr Carter is the first recipient of the award from a professional services company supporting industry.

He founded Commercial Eyes in 2001 as a third-party provider of commercialisation services, following a long career in the pharmaceutical industry. The company now has over 65 employees, working with up to 50 clients at any one time, and is Australia’s leading provider of outsourced regulatory, reimbursement and medical services.

In his presentation of the award, Medicines Australia Chair, Dr Martin Cross, acknowledged the important role Mr Carter and Commercial Eyes play in supporting companies to bring important medicines into the Australian market – through advice, guidance and expertise. He also mentioned Mr Carter’s support of many charitable and non-profit organisations.

According to Medicines Australia, Mr Carter has actively participated in its policy development, through committee membership in Medicines Australia, where he has provided ongoing support to deliver on strategic priorities focusing on the health and growth of the innovative biopharmaceutical sector in Australia.

“It’s a real honour to have been recognised in this way and a testament to the valuable contribution that the professional service industry makes to the Australian medicine industry,” Mr Carter said. “It’s also a public acknowledgement that a career in professional services is valid, valuable and indeed vital to the medicine industry.”

Mr Carter follows last year’s award winner, Amgen’s Sara Pantzer. Previous winners also include Michelle Burke from Bristol-Myers Squibb, Pfizer’s Mendal Grobler and Novartis’ Mitch Kirkman.